Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial calendar
    • Research
    • Articles
    • Insider transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Learn
    • Investing School
    • Q&A
    • Analysis school
  • About us
    • Our coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

8.06

 

EUR

 

+2.03 %

5,414 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Compare
+2.03%
-0.49%
+2.03%
+34.33%
+113.79%
+234.44%
+70.04%
+437.91%
-98.67%

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
57.72M EUR
Turnover
83.07K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
04.03.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 04.03.2025

Latest extensive report

Released: 06.10.2023

Revenue and EBIT-%
21.721.714.414.47.27.2008.8-16.9-6.121.723.129.322222323242425e25e26e26e27e27e

Revenue M

EBIT-% (adj.)

EPS and dividend
0.90.90.50.50.20.2-0.2-0.222222323242425e25e26e26e27e27e

EPS (adj.)

Dividend %

Financial calendar
27.3.
2025

General meeting '25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Nexstim: Returning to the buy side after a share price decline
Research19 hours ago by
Antti Siltanen

Nexstim: Returning to the buy side after a share price decline

Nexstim's share price has fallen sharply in recent days, and the risk/reward ratio has become attractive again

Nexstim
Regulatory press releaseyesterday

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Regulatory press releaseyesterday

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Nexstim H2'24: Solid growth in line with expectations
Research2/28/2025, 8:13 AM by
Antti Siltanen

Nexstim H2'24: Solid growth in line with expectations

Nexstim's H2'24 was in line with our expectations, with revenue up 17%.

Nexstim
Regulatory press release2/27/2025, 7:00 AM

NEXSTIM PLC’S FINANCIAL STATEMENTS BULLETIN 2024

Nexstim
Nexstim H2'24 preview: Profitable H2 in expectations
Analyst Comment2/25/2025, 6:54 AM by
Antti Siltanen

Nexstim H2'24 preview: Profitable H2 in expectations

Nexstim will publish its H2 report on Thursday, February 27 at 9 am EET. The second half of an eventful year full of surprises was marked in particular by the cooperation agreement with Brainlab and the import license for the Indian market.

Nexstim
Press release2/24/2025, 1:00 PM

Notice of Nexstim Plc’s 2024 Full Year Results

Nexstim
Regulatory press release2/18/2025, 7:00 AM

Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting

Nexstim
Press release2/17/2025, 8:00 AM

Distributor Orders Nexstim NBS System 5 for European Hospital

Nexstim
Regulatory press release1/15/2025, 7:00 AM

Insider Information: Nexstim Plc and Sinaptica Therapeutics, Inc. Announce Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease

Nexstim
Press release1/9/2025, 7:00 AM

Nexstim Receives NBS 5 System Order from New Customer in Ohio, United States

Nexstim
Research1/3/2025, 7:58 AM by
Antti Siltanen

Nexstim: Good end to a strong year

Nexstim's strong 2024 culminated in a seasonally busy Q4 sales season. The total number of system sales reported for the year was 28, up from 24 last year and the best sales year in Nexstim's history.

Nexstim
Press release1/2/2025, 7:00 AM

Nexstim Plc: Henri Hannula appointed as CCO

Nexstim
Regulatory press release12/30/2024, 12:30 PM

Nexstim Plc’s Financial Information and Annual General Meeting in 2025

Nexstim
Regulatory press release12/30/2024, 12:00 PM

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release12/23/2024, 1:00 PM

Nexstim Plc: Conversion of stock options 2023A to stock options 2023B and 2023C

Nexstim
Press release12/20/2024, 7:00 AM

Delve Psychiatry in Nevada, United States Orders Nexstim NBS 5+ System

Nexstim
Press release12/19/2024, 8:00 AM

Nexstim Receives NBS 6 Order from University Hospital in California

Nexstim
Press release12/18/2024, 7:00 AM

Distributor Orders Two Nexstim NBS 5 Systems

Nexstim
Press release12/17/2024, 7:00 AM

Finnish University Hospital Orders Nexstim NBS System 5

Nexstim
Forum discussions
Tässä on Antin tekemä tuore yhtiöraportti Nexstimistä. Nexstimin osakekurssi on laskenut viime päivinä rivakasti ja sen myötä tuotto/riski-suhde on kääntynyt jälleen houkuttelevaksi. Nostammekin suosituksemme lisää-tasolle (aik. vähennä) ja toistamme tavoitehintamme 9,0 euroa. Yhti...
19 hours ago
by Sijoittaja-alokas
22
Yahoo Finance 3 European Stocks Estimated To Be Undervalued In March 2025 As European markets navigate a complex landscape of mixed inflation data and economic contractions in major economies like Germany and France, the pan-European STOXX Europe 600 Index has shown resilience by...
yesterday
by Jatast
18
Weckroth myi siis kaikki (yksityishenkilönä) omistamansa 4433 osaketta, mutta omisti 28.2. edelleen WRCC Consultingin kautta 137 491 osaketta. Mikko Karvinen sanoi torstaina, että sisäpiiritieto on estänyt sijoittamasta edelliset pari vuotta. Hallituksen jäsentä sisäpiiritieto ei...
yesterday
11
Voisi kuvitella että on päässyt käymään esimerkiksi sellainen tilanne että vaihtovelkakirjaa on silloin aikoinaan tullut merkattua niin paljon kun vaan suinkin on saanut rahaa irroitettua ja nyt on sitten jotain kuluja, bullet-laina tai vastaavaa rahanmenoa ja oli pakko jostain irroittaa...
yesterday
by Kyhnykeisari
5
jos sisäpiiritieto on positiivinen estetään ostamasta, mutta ei myymästä. Jos sisäpiiritieto on negatiivinen, estetään myymästä ja sallitaan ostamisen. Tässä tapauksessa toimari ei ole pystynyt ostamaan osakkeita omien sanojensa mukaan. Voiko tästä tehdä jotain johtopäätöksiä? Ehk...
yesterday
4
Inderes Nexstim Oyj: Johdon liiketoimet, Weckroth - Inderes Yhtiötiedote, Helsinki, 03.03.2025 klo. 14.00 (EET)Nexstim Oyj: Johdon liiketoimet, WeckrothNexstim Oyj (NXTMH:HEX) (”Nexstim” tai ”Yhtiö”) ilmoittaa johdon liiketoimista seuraavasti:Ilmoitusvelvollin... Tero Weckroth, myynyt...
yesterday
by BossoB
4
Korjataan sen verran, että perjantaina ja tänään myytyjen osakkeiden yhteiskauppahinta oli 38 654€. Tätä kirjoittaessa Weckrothille jääneiden osakkeiden arvo on pudonnut pelkästään tänään 98 994€.
yesterday
3
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial calendar
    • Research
    • Articles
    • Insider transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Learn
    • Investing School
    • Q&A
    • Analysis school
  • About us
    • Our coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.